Antibodies targeting talaromyces marneffei mp1p protein and methods of use thereof
US-2024199726-A1 · Jun 20, 2024 · US
US10766951B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10766951-B2 |
| Application number | US-201615563614-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 1, 2016 |
| Priority date | Apr 1, 2015 |
| Publication date | Sep 8, 2020 |
| Grant date | Sep 8, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Anti-CaENO1 antibodies and humanized antibodies are provided as an effective diagnostic agent or a therapeutic treatment against infections caused by Candida spp., preferably Candida albicans, Candida tropicalis, fluconazole resistance Candida spp., Streptococcus, Staphylococcus.
Opening claim text (preview).
What is claimed is: 1. An isolated anti-CaENO1 antibody or an antigen-binding portion thereof, comprising a light chain complementarity determining region 1 (L-CDR1) of SEQ ID NO:5; a light chain CDR2 (L-CDR2) of SEQ ID NO:6; and a light chain CDR3 (L-CDR3) of SEQ ID NO:7; and a heavy chain CDR1 (H-CDR1) of SEQ ID NO:8; a heavy chain CDR2 (H-CDR2) of SEQ ID NO:9; and a heavy chain CDR3 (H-CDR3) of SEQ ID NO:10; such that said isolated antibody or antigen-binding portion thereof binds to CaENO1. 2. The antibody of claim 1 , wherein the isolated anti-CaENO1 antibody is a monoclonal antibody, chimeric antibody or humanized antibody. 3. The antibody of claim 1 , wherein the light chain of the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:13 and 14; or wherein the heavy chain of the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 15 and 16. 4. The antibody of claim 1 , which is a humanized antibody comprising (i) a light chain having an amino acid sequence selected from the group consisting of SEQ ID NOs:13 and 14, and (ii) a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NOs:15 and 16. 5. The humanized antibody of claim 4 , which comprises: (i) a light chain having an amino acid sequence of SEQ ID NO:13 and (ii) a heavy chain having an amino acid sequence of SEQ ID NO: 15 or (iii) a light chain having an amino acid sequence of SEQ ID NO: 14 and (iv) a heavy chain having an amino acid sequence of SEQ ID NO: 16.
Staphylococcus · CPC title
from eggs · CPC title
for enzymes or isoenzymes · CPC title
from yeast · CPC title
Streptococcus · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.